Search This Blog

Thursday, September 29, 2016

Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations

Amgen to Receive Worldwide Exclusive License to Arrowhead's RNAi ARC-LPA Program
Amgen Receives Exclusive License Option to RNAi Therapy for Undisclosed Cardiovascular Target
Arrowhead to Receive $56.5 Million in Upfront Payments and Initial Equity Investment and up to an Additional $617 Million in Potential Milestone and Equity Payments
Arrowhead Will Hold a Webcast Today at 9 a.m. ET

Amgen - Investors - RSS Content

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.